GRAIL (NASDAQ:GRAL) Stock Price Down 7.6% – Here’s Why

GRAIL, Inc. (NASDAQ:GRAL)’s share price fell 7.6% during mid-day trading on Friday . The stock traded as low as $69.75 and last traded at $70.0250. 125,960 shares changed hands during trading, a decline of 87% from the average daily volume of 988,306 shares. The stock had previously closed at $75.79.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Multiple law firms announced or reminded investors about a pending securities class-action lawsuit against GRAIL, with lead-plaintiff deadlines centered on August 4, 2026. Article Title
• Neutral Sentiment: Additional firms, including The Gross Law Firm, Schall, and BFA Law, publicized the same lawsuit and encouraged affected investors to seek participation or counsel, extending the visibility of the case. Article Title
• Neutral Sentiment: Several July 9 notices from other plaintiff firms repeated the same allegations, describing the stock decline after the NHS-Galleri trial results as the catalyst for investor losses and class-action claims. Article Title
• Negative Sentiment: The lawsuit campaign keeps attention on GRAIL’s February 20, 2026 trial readout, which previously erased more than $2.2 billion in market value and remains the key reason investors are focused on the stock’s downside risk. Article Title

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Robert W. Baird set a $70.00 price target on shares of GRAIL in a research report on Wednesday, May 6th. The Goldman Sachs Group began coverage on GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 target price on the stock. Wolfe Research started coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, TD Cowen lifted their price target on GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, GRAIL has a consensus rating of “Hold” and an average price target of $67.00.

GRAIL Price Performance

The company has a fifty day simple moving average of $63.84 and a two-hundred day simple moving average of $70.00. The company has a market capitalization of $3.06 billion, a P/E ratio of -6.83 and a beta of 3.22.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.47. The business had revenue of $40.78 million during the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. Equities analysts anticipate that GRAIL, Inc. will post -10.91 earnings per share for the current year.

Insider Activity

In other news, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.83% of the company’s stock.

Institutional Investors Weigh In On GRAIL

Several large investors have recently modified their holdings of GRAL. Farallon Capital Management LLC grew its position in GRAIL by 73.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after acquiring an additional 993,684 shares during the period. Morgan Stanley lifted its position in GRAIL by 63.8% during the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after purchasing an additional 588,647 shares during the period. State Street Corp raised its position in shares of GRAIL by 38.8% during the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after acquiring an additional 510,546 shares during the last quarter. Baker BROS. Advisors LP raised its position in shares of GRAIL by 27.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after acquiring an additional 455,208 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in GRAIL during the 4th quarter worth $37,874,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.